{
  "title": "Model Explanation & Detailed IVIG Artifact Analysis",
  "sections": [
    {
      "title": "Pre-Venetoclax Phase (Dara CyBorD) – Gompertz Model",
      "content": [
        "• y(t) = A·exp(-B·exp(-C·t))",
        "  - Captures initial rapid kill under Dara CyBorD and plateau as resistant subclones emerge.",
        "  - Projected κ by Oct 1, 2025: {proj_pre_final:.1f} mg/L (no CR reached)."
      ]
    },
    {
      "title": "Post-Venetoclax Phase (Dara + Ven + Dex) – Exponential Model",
      "content": [
        "• y(t) = A·exp(-k·t)",
        "  - Reflects continuous BCL-2–dependent apoptosis enhanced by Daratumumab and Dex.",
        "  - Projected VGPR (<{vgpr} mg/L) by {vgpr_date:%b %d, %Y}.",
        "  - Projected CR  (<{cr} mg/L) by {cr_date:%b %d, %Y}."
      ]
    },
    {
      "title": "Clinical Timeline Notes",
      "content": [
        "• Treatment Regimen Evolution:",
        "  - Dara CyBorD started: February 14, 2025",
        "  - Changed to Dara Venetoclax Dex: April 10, 2025",
        "  - Last dose of Dexamethasone: June 19, 2025",
        "  - Dara Ven only: June 26, 2025 going forward",
        "  - Currently considering Venetoclax monotherapy",
        "",
        "• Treatment Optimization:",
        "  - Venetoclax absorption optimization discovered: July 4, 2025 (40g fat intake)"
      ]
    },
    {
      "title": "IVIG Impact Assessment",
      "content": [
        "• IVIG Administration:",
        "  - First dose: May 8, 2025 (30 g)",
        "  - Second dose: June 8, 2025 (30 g)",
        "  - Third dose: July 11, 2025 (30 g)",
        "",
        "• Lambda Analysis:",
        "  - λ dropped to 1.4 mg/L on May 1 (before first IVIG)",
        "  - Remained at 1.4 mg/L throughout = assay detection limit",
        "  - No evidence of λ artifacts from IVIG",
        "",
        "• Kappa Trajectory:",
        "  - Post-venetoclax: 176.8 → 134.4 → 104.8 → 84.3... → 23.2 → 20.3 mg/L",
        "  - Shows progressive slowing as it approaches and achieves CR threshold",
        "",
        "• Potential IVIG Contribution Calculation:",
        "  - 30g IVIG contains ~5.25g κ light chains",
        "  - In 5L plasma: 1,050 mg/L total κ pool",
        "  - Even 1% release = 10.5 mg/L artifact",
        "  - May contribute to observed κ levels, but magnitude unclear",
        "",
        "• Clinical Interpretation:",
        "  - Primary pattern: natural treatment response kinetics",
        "  - IVIG may contribute some artifact, but not definitively quantifiable",
        "  - Latest κ = 20.3 mg/L (July 10) has achieved CR assuming some IVIG artifact (<19.4 mg/L)",
        "  - Continued decline confirms sustained response despite potential IVIG artifacts"
      ]
    }
  ]
}
